Overview
- Zydus Lifesciences and its U.S. unit agreed to a $120 million payment to resolve a patent dispute over Astellas’ bladder disorder drug Mirabegron, sold as Myrbetriq.
- Under the deal, Zydus will pay a prepaid per‑unit licensing fee on U.S. sales of its Mirabegron generic from the agreement date through September 2027.
- The settlement permits Zydus to keep marketing its Mirabegron generic in the United States.
- The companies said other terms are confidential, leaving key commercial details undisclosed.
- The announcement follows Lupin’s recent $90 million settlement with Astellas over the same drug, which Citi has flagged as potentially limiting near‑term competition from additional generics.